CureXcell® + Sham injection
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lower Extremity Chronic Ulcers in Diabetics
Conditions
Lower Extremity Chronic Ulcers in Diabetics
Trial Timeline
Aug 1, 2011 → Oct 1, 2015
NCT ID
NCT01421966About CureXcell® + Sham injection
CureXcell® + Sham injection is a phase 3 stage product being developed by ICON plc. for Lower Extremity Chronic Ulcers in Diabetics. The current trial status is completed. This product is registered under clinical trial identifier NCT01421966. Target conditions include Lower Extremity Chronic Ulcers in Diabetics.
What happened to similar drugs?
5 of 13 similar drugs in Lower Extremity Chronic Ulcers in Diabetics were approved
Approved (5) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01421966 | Phase 3 | Completed |
Competing Products
20 competing products in Lower Extremity Chronic Ulcers in Diabetics